Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -96.42M | -104.93M | -116.05M | -115.33M | -131.74M |
| Total Depreciation and Amortization | 3.17M | 2.58M | 2.34M | 2.53M | 2.58M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.70M | 23.14M | 27.82M | 18.66M | 21.59M |
| Change in Net Operating Assets | 14.08M | 8.63M | 7.13M | 4.17M | 248.00K |
| Cash from Operations | -55.46M | -70.58M | -78.76M | -89.97M | -107.32M |
| Capital Expenditure | -26.78M | -25.91M | -17.95M | -10.37M | -5.97M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.04M | 166.16M | 76.18M | 61.36M | -82.43M |
| Cash from Investing | 77.26M | 140.26M | 58.24M | 51.00M | -88.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.70M | -13.54M | -13.54M | -13.54M | -13.54M |
| Issuance of Common Stock | 190.00K | 241.00K | 147.00K | 79.00K | 251.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.22M | -11.96M | -14.23M | -6.97M | 199.38M |
| Cash from Financing | -25.74M | -25.26M | -27.63M | -20.43M | 186.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.94M | 44.42M | -48.16M | -59.40M | -9.64M |